Results 81 to 90 of about 2,398,808 (296)

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

Translating whole‐genome doubling into precision medicine in cancer

Molecular Oncology, EarlyView.
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley   +1 more source

Supplementary Data from EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma

, 2010
Supplementary Data from EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial ...
Rebecca L. Stone (214799), Ju-Won Roh (14904557), Hee-Dong Han (14902776), Nicholas B. Jennings (14904554), Hye-Sun Kim (50212), Alpa M. Nick (14888571), John Gooya (14982833), Jeong-Won Lee (770820), Mian M.K. Shahzad (14902779), Lingegowda S. Mangala (14888565), Sun Joo Lee (4060375), Shenlan Mao (1504684), Anil K. Sood (149701), Robert L. Coleman (14667236), Eun Ji Nam (1447849), Dowdy Jackson (508976)   +15 more
core   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Spatial biology in cancer epigenetics

Molecular Oncology, EarlyView.
Spatial epigenomics combines molecular profiling with tissue architecture to reveal how gene regulation is organized within intact tissues. In cancer, these technologies uncover the mechanisms driving tumor heterogeneity and microenvironmental interactions, opening new opportunities for biomarker discovery and precision medicine.
Eva Crespo‐García, Manel Esteller
wiley   +1 more source

AI-driven innovation in antibody-drug conjugate design

Frontiers in Drug Discovery
Antibody-drug conjugates (ADCs) represent a mechanistically defined class of targeted therapeutics that combine monoclonal antibodies with cytotoxic payloads to achieve selective delivery to antigen-expressing carcinoma cells.
Heather A. Noriega, Xiang Simon Wang
doaj   +1 more source

ADP‐ribosylation: An emerging regulator of the epigenome

Molecular Oncology, EarlyView.
ADP‐ribosylation has emerged as a dynamic epigenetic signaling mechanism that modifies histones and chromatin‐associated proteins. Through coordinated PARylation and MARylation, it integrates with other histone modifications to regulate chromatin structure, transcription factor activity, and gene expression, influencing genome function and disease ...
Cristel V. Camacho, Chenqian Liu, W. Lee Kraus   +2 more
wiley   +1 more source

Sacituzumab Govitecan, a Novel Antibody–Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma [PDF]

, 2016
Patients with metastatic, platinum-resistant urothelial carcinoma (PRUC) have no Food and Drug Administration–approved therapies. The response rates to second-line chemotherapy have generally been < 20%, with a median overall survival of < 1 year.
Hajdenberg, Julio, Goldenberg, David M., Nanus, David M., Sharkey, Robert M., Tagawa, Scott T., Ocean, Allyson J., Hodes, Gillian, Faltas, Bishoy, Govindan, Serengulam V., Wilhelm, Francois   +9 more
core   +1 more source

Targeted drug conjugates in cancer therapy: Challenges and opportunities

Pharmaceutical Science Advances
Traditional chemotherapy is often accompanied by off-target toxicity, resulting in adverse side effects and driving the development of targeted therapies.
Geng Jia, Yuqi Jiang, Xiaoyang Li
doaj   +1 more source

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

Molecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee, Alessia Marin, Shivani Yalala, Harri M. Itkonen   +3 more
wiley   +1 more source